Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)

NCT00783471 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
51
Enrollment
OTHER
Sponsor class

Stopped The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both treatment arms.

Conditions

Interventions

Sponsor

Hellenic Cooperative Oncology Group